Back to School: How biopharma can reboot drug development. Access exclusive analysis here

NICE appraises Xeloda, UFT

The U.K.'s National Institute for Clinical Excellence (NICE) issued guidance on the use of Xeloda capecitabine from Roche (SWX:ROCZ) for breast cancer

Read the full 222 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE